Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT05311878 Completed - Healthy Subjects Clinical Trials

Non-invasive BCI for Cognitive Enhancement

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

People's perceptual skills can significantly affect their abilities to make optimal decisions, judgments, and actions in real-world dynamic environments. Perceptual learning refers to training and experiences to induce improvements in the ability to make sense of what people see, hear, feel, taste or smell based on ambiguous sensory information. In this study, investigators hypothesise that there exist neural signatures that robustly encode the conscious visual perception of rotations of a cursor and the magnitudes of these rotations in a novel, rotation-based perceptual learning task. Investigators also hypothesise that online, instantaneous EEG-based feedback on subjects' visual perceptions of rotations with an EEG-based Brain Computer Interface (BCI) can foster perceptual learning much more effectively than behaviour perceptual training, especially in very small rotation magnitudes that represent extremely difficult perceptual tasks.

NCT ID: NCT05309915 Completed - Healthy Subjects Clinical Trials

A Study of STP707 Administered by IV in Healthy Subjects

Start date: February 28, 2022
Phase: Phase 1
Study type: Interventional

Single center study, randomized, to evaluate safety, tolerability, PK of single ascending dose of STP707 when administered by IV infusion in healthy subjects.

NCT ID: NCT05297968 Completed - Healthy Subjects Clinical Trials

Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension

Start date: May 13, 2021
Phase: Phase 1
Study type: Interventional

an open label,balanced,randomized,two-treatment,two-period,two-sequence,single dose,crossover,oral bioequivalence Study of oseltamivir phosphate for oral suspension in healthy ,adult,human subjects under fasted/fed conditions.

NCT ID: NCT05293171 Completed - Healthy Subjects Clinical Trials

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Start date: June 11, 2021
Phase: Phase 1
Study type: Interventional

The study will assess the corrected QT (QTc) effects (electrocardiogram [ECG]) of BL-8040 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.

NCT ID: NCT05265338 Completed - Healthy Subjects Clinical Trials

A Food Effect Study of KC1036 in Healthy Subjects

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The primary objective of the study was to assess the effect of High Fat Diet on the pharmacokinetics of KC1036 in Chinese adult healthy subjects.

NCT ID: NCT05259189 Completed - Healthy Subjects Clinical Trials

A Study of NBL-012 in Healthy Chinese Subjects

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics (PK) of NBL-012 as single ascending doses (SAD) administered subcutaneously to healthy Chinese subjects.

NCT ID: NCT05241535 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Start date: January 12, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.

NCT ID: NCT05236998 Completed - Healthy Subjects Clinical Trials

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Start date: November 3, 2021
Phase: Phase 1
Study type: Interventional

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.

NCT ID: NCT05227768 Completed - Healthy Subjects Clinical Trials

Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

Start date: November 11, 2021
Phase: Phase 1
Study type: Interventional

The study consists of 5 dose groups, starting at 25 mg, 6 subjects in 25 mg group, and 8 subjects in each other group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and PK characteristics. The subject number of single dose group may increase or decrease depending on the safety and PK data obtained. The dose levels are planned at 25 mg, 200 mg, 400 mg, 800 mg and 1200 mg. Based on observed tolerability and safety data or obtained PK data, adjustments are allowed at all dose levels in the clinical trial.

NCT ID: NCT05221138 Completed - Healthy Subjects Clinical Trials

Food Effect on Pharmacokinetic Profiles of VV116 Administered Orally to Chinese Healthy Volunteers

Start date: December 30, 2021
Phase: Phase 1
Study type: Interventional

This study is a single-center, randomized, open-label, three-period crossover design, the objective is to evaluate the pharmacokinetics and safety of VV116 tablets, which are orally administered to Chinese healthy volunteers after fasting, standard diet or high-fat diet.